Pet Cancer Therapeutics Market

The global Pet Cancer Therapeutics Market is valued at USD 411 Million in 2023 and is projected to reach a value of USD 971 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 10.1% between 2024 and 2032.

Key Highlights of Pet Cancer Therapeutics Market

• In 2023, the North American continent dominated the market for Pet Cancer Therapeutics, accounting for 72.2% of the total market share,
• The Asia Pacific region is expected to experience significant growth throughout the forecast period,
• In 2023, the Chemotherapy segment took the lead in the Pet Cancer Therapeutics market, contributing 63.1% of considerable revenue share,
• Based on Species, the Dogs category significantly contributed to the Pet Cancer Therapeutics market’s expansion in 2023
• Adopting telemedicine and remote monitoring technologies facilitates access to specialized pet cancer care, especially in remote areas. Teleconsultations, virtual follow-up visits, and remote monitoring of treatment outcomes are becoming more prevalent. For instance, PetCure Oncology provides telehealth services to families of pets diagnosed with cancer. Their fast & convenient telehealth solution offers enhanced accessibility to cancer care for a broader range of pet owners and veterinarians across the country. Additionally, their team of certified radiation oncologists is available virtually to discuss imaging findings and treatment choices and address queries regarding the health of dogs or cats

Pet Cancer Therapeutics Market: Regional Overview

In 2023, the North America Pet Cancer Therapeutics market demonstrated remarkable dominance, capturing a staggering 72.2% of the revenue share. This significant share reflects the growing recognition of pets as cherished family members, with pet ownership reaching unprecedented levels. Over one-third of households worldwide and approximately 70% in the U.S. include pets. Consequently, companies are increasingly focusing on animal health, dedicating resources to developing groundbreaking treatments for debilitating diseases like cancer. With substantial investments in research and cutting-edge technologies, these companies strive to expand and expedite drug discovery efforts. By offering pet owners more effective treatment options, they aim to elevate the health and well-being of companion animals.

U.S. Pet Cancer Therapeutics Market Overview

The U.S. Pet Cancer Therapeutics market, valued at USD 200.1 million in 2023, is anticipated to soar to approximately USD 477.3 million by 2032. Projections suggest a noteworthy Compound Annual Growth Rate (CAGR) of 10.16% from 2024 to 2032. With an estimated population of around 65 million dogs and 32 million cats in the United States, the National Cancer Institute highlights the significant incidence of cancer in pets. Roughly 6 million new cancer diagnoses are reported annually in both dogs and cats, offering a substantial opportunity to study spontaneous cancers akin to those observed in humans.

Pet Cancer Therapeutics Market: Therapy Overview

• In 2023, the Chemotherapy segment asserted its dominance in the Global Pet Cancer Therapeutics market, commanding 63.1% of the revenue share. Based on Therapy, the Global Pet Cancer Therapeutics market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy, and Combination Therapy.
• Chemotherapy emerges as a primary treatment modality for animal cancer, demonstrating remission in over 70% of cases. Particularly, dogs with cancer, predominantly lymphoma, exhibit a remarkable healing rate of more than 95% with appropriate chemotherapy protocols. Chemotherapy employs drugs to eradicate or impede the growth of cancer cells. It is a standard treatment for various pet cancers such as lymphoma, mast cell tumors, & osteosarcoma. Protocols are tailored to the cancer type, stage, and the pet's overall health, yielding significant impacts on survival rates while maintaining a balance with potential adverse effects.

Key Trends

1. There's a rising prevalence of cancer in pets worldwide. This trend is due to factors such as environmental pollutants, genetic predisposition, and an aging pet population.
2. Better diagnostic techniques, such as MRI, CT scans, or laboratory tests, facilitate early detection and accurate cancer diagnosis in pets, leading to prompt treatment.
3. The trend towards personalized cancer treatment in dogs is similar to that of human medicine. It is becoming more common to choose treatments based on the individual pet's genetic makeup, tumor type, and response to therapy.
4. The pet cancer therapeutic market diversifies treatment options, including chemotherapy, radiation therapy, surgery, immunotherapies, targeted therapies, and emerging modalities such as gene therapy and nanomedicine.
5. Pharmaceutical companies & research institutions are investing significantly in developing novel therapeutics and treatment modalities for pet cancer. This includes exploring new drug formulations, targeted therapies, and immunotherapies specifically designed for pets.
6. As the cost of treating pet cancer continues to rise, there is an increasing demand for pet insurance. Pet owners are looking for comprehensive insurance plans covering diagnostics, treatment and monitoring of cancer to increase the growth of the cat insurance market.

Advances in Canine Cancer Treatment: Breakthrough Therapies and Approvals

• USDA Approval for ELIAS Cancer Immunotherapy: In January 2024, ELIAS Animal Health achieved a critical milestone as the U.S. Department of Agriculture (USDA) acknowledged the efficacy of ELIAS Cancer Immunotherapy (ECI®) for treating bone cancer in dogs. This groundbreaking therapy, a first-in-class adoptive cell therapy, targets osteosarcoma, a fatal form of bone cancer in canines.
• Full FDA Approval for Tanovea: Elanco Animal Health Incorporated attained full FDA approval for Tanovea, marking a milestone in canine lymphoma treatment. Tanovea, initially conditionally approved, underwent rigorous evaluation, becoming one of the most extensively studied options for treating canine lymphoma. This approval underscores the robust scientific evidence supporting Tanovea's efficacy and safety, providing veterinarians with a reliable treatment option for guiding canine patients through their lymphoma treatment journey.
• FDA Approval for STELFONTA: QBiotics Group Limited received FDA approval for STELFONTA, the first-ever FDA-approved treatment for all grades of canine non-metastatic mast cell tumors. With previous approvals in major European markets, STELFONTA's U.S. approval addresses a critical need in canine cancer therapy, particularly for mast cell tumors, the most commonly diagnosed cancer in dogs.
• Virbac's Non-Surgical Cancer Treatment: Virbac Corporation introduced STELFONTA, an innovative cancer treatment derived from an Australian rainforest plant, for canine mast cell tumors. This non-surgical alternative, injected directly into the tumor, activates the local immune system, leading to tumor destruction and promoting complete healing with minimal scarring. The availability of STELFONTA offers veterinarians a novel approach to managing mast cell tumors in dogs.
• ELIAS Animal Health's Immunotherapy Research: ELIAS Animal Health unveiled promising research demonstrating the cancer-killing capabilities of its Activated T Cell Immunotherapy. This personalized immunotherapy, presented at the 2022 American College of Veterinary Internal Medicine Forum, stimulates the patient's immune system to recognize and attack cancer cells. The therapy, utilizing a patient's own cancer cells to prime and activate immune cells ex vivo, represents a significant advancement in personalized cancer treatment for pets.

Premium Insights

With advancements in pet healthcare, diet, and preventive measures, pets live longer lives, increasing the prevalence of diseases common in aging animals, notably cancer. As the leading cause of death in dogs over one year old, accounting for nearly one-third of all fatalities, cancer has become a significant concern for pet owners and veterinary professionals alike. Consequently, there's a heightened focus on developing more accessible and efficient cancer treatment methods. Common types of cancer affecting dogs include lymphoma, bone cancer, skin cancer, splenic or liver tumors, and bladder cancer. In contrast, lymphoma, mammary tumors, oral tumors, and other types are prevalent in cats. E.g., Boehringer Ingelheim and CarthroniX have joined forces in a strategic partnership to explore small molecule therapeutics for canine oncology. Boehringer Ingelheim, a renowned global leader in animal health, and CarthroniX, a biopharmaceutical company specializing in small molecule-based therapies for degenerative and aging-related diseases, aim to identify novel molecules targeting cancers in dogs.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Driving Factors of the Pet Cancer Therapeutics Market

The rapid uptake of innovative pet care medications propels market growth, fueled by increased pet adoptions, particularly dogs and cats, attributed to higher disposable incomes. The escalating incidence of pet cancer and augmented expenditure on pet healthcare catalyze global market expansion. Manufacturers' intensified research efforts in combating pet cancer led to introducing novel products, enhancing market dynamics. Top players boasting robust product portfolios are poised to amplify their market presence with groundbreaking treatments.

Dominance of Dog Cancer Therapeutics

In the species segment, the dog cancer therapeutics market emerges as the revenue leader globally, driven by abundant marketed drugs and vaccines for canine cancer treatment. With cancer ranking as the primary cause of death in nearly half of dogs, especially those over ten years old, the demand for cancer therapeutics is on the rise, fostering market growth. As reported by the Veterinary Cancer Society, cancer accounts for the primary cause of death in approximately 47% of dogs, particularly those aged ten and above. This underscores a growing requirement for cancer treatments in dogs, potentially leading to an increased demand for cancer therapeutics.

Advancements in Veterinary Oncology

The field of veterinary oncology experiences significant advancements, propelled by technological innovations & breakthrough research. Enhanced diagnostic capabilities facilitate early cancer detection, empowering veterinarians to initiate prompt treatment. Early detection of cancer, which enables veterinarians to start treatment as soon as possible, is facilitated by the enhanced diagnostic capabilities. Furthermore, developing targeted therapies, immunotherapies, and new treatment modalities is stimulated by insight into cancer biology in pet animals.

Rise in Pet Health Awareness

Increased awareness of pet health fuels market expansion, exemplified by initiatives like Calviri Inc., which completed the enrollment of 800 dogs in the Vaccine Against Canine Cancer Study (VACCS). This is the largest interventional canine clinical trial to date. These initiatives heighten awareness of canine cancer among healthcare organizations, presenting growth opportunities for the segment during the forecast period.

Competitive Landscape

The competitive landscape within the Pet Cancer Therapeutics market is influenced by innovations, strategic acquisitions, and collaborative ventures. For instance, Anivive Lifesciences, a pet health technology company committed to addressing unmet needs in the veterinary domain, has announced that Dechra Pharmaceuticals PLC (Dechra) has acquired the rights to Laverdia™-CA1 (verdinexor), a groundbreaking treatment for canine lymphoma. Developed by Anivive, Laverdia-CA1 aims to overcome common barriers preventing dogs from accessing cancer treatment, including cost, convenience, and concerns about side effects. With Laverdia-CA1 tablets, which are obtainable by prescription from veterinarians, pet owners can administer the treatment at home, empowering them to pursue treatment options upon discovering their dog's lymphoma diagnosis. Under the terms of the agreement, Dechra assumes responsibility for selling, marketing, and providing support for Laverdia-CA1 in the United States.

Recent Market Developments

• In June 2024, two prominent entities in the U.S. pet sector, Adopt a Pet and Zoetis, have announced the first cohort of pet welfare organizations chosen to receive the 2024 Zoetis pet care product grant. These grants are integral to an exclusive collaboration in pet health to enhance access to care and resources for pets, shelters, rescues, and veterinary healthcare teams throughout the United States.
• In April 2024, ELIAS Animal Health, a prominent company specializing in companion animal cancer therapeutics, is expanding its manufacturing capacity by moving to a larger facility situated in Lenexa, Kansas. This expansion comes in anticipation of the forthcoming commercial launch of the ELIAS Cancer Immunotherapy (ECI®) later this year. In January 2024, the USDA recognized ECI® as demonstrating a reasonable expectation of efficacy, marking a significant milestone in its journey toward product licensure and a noteworthy advancement in veterinary oncology. ECI® is poised to become the sole adoptive cell therapy approved for the treatment of canine osteosarcoma, a fatal type of bone cancer in dogs.
• In April 2024, ELIAS Animal Health has appointed Brian Segebrecht as its Chief Revenue Officer in anticipation of the imminent approval of the ELIAS Cancer Immunotherapy (ECI®) in Q4. Alongside this appointment, ELIAS Animal Health has initiated efforts to secure $10 million in Series A funding to support the commercialization and advancement of innovative therapies for canine cancer. Segebrecht brings valuable experience to the ELIAS leadership team, having previously served as CEO of Sentrx Animal Care, guiding the company to a successful exit in 2023.
• In January 2024, Elanco Animal Health Incorporated has initiated a pioneering, multi-year campaign aimed at rescuing 1 million puppies from avoidable death caused by the highly infectious canine parvovirus (parvo). Known as the Defend Puppies. Defeat Parvo. The initiative's objective is to combat a virus with a mortality rate as alarming as 91% when not promptly and aggressively treated. Approximately 900 dogs are estimated to be affected by this virus annually.

The global Pet Cancer Therapeutics market can be categorized as Therapy, Route of Administration, Species, Application, and Region.